SAEs, or AEs leading to study drug discontinuation were not seen in any of the arms, whether MTX was added or not.

Table 1. Efficacy through 24 Weeks in the LTE RA-BEYOND Study for Patients Not Rescued in RA-BEGIN

		MTX to Bari			Bari to Bari			Bari+MTX to Bari		
		(N=69, +MTX); (N=67, -MTX)	Wk 52 Wk 64 Wk 76		(N=67, +MTX); (N=57, -MTX)	Wk 52 Wk 64 Wk 76		(N=87, +MTX); (N=76, -MTX)	Wk 52 Wk 64 Wk 76	
ACR20+, %	+MTX	84.1	88.4	94.2	86.6	86.6	86.6	89.7	87.4	87.4
	-MTX	83.6	86.6	82.1	94.7	87.7	87.7	97.4	90.8	86.8
ACR50+, %	+MTX	53.6	62.6	81.2	64.2	71.6	70.1	77.0	71.3	71.3
	-MTX	61.2	79.1	71.6	77.2	82.5	80.7	85.5	77.6	77.6
ACR70+, %	+MTX	34.8	65.2	59.4	40.3	49.3	53.7	55.2	51.7	52.9
	-MTX	44.8	62.7	62.7	63.2	66.7	68.4	65.8	55.3	56.6
CDAP	+MTX	12.1	7.6**	6.9**	10.0	6.7**	6.6**	8.5	9.3	8.4
	-MTX	8.9	4.4**	4.9**	5.5	4.5	4.0*	5.2	4.7	5.9
SDAP	+MTX	13.1	8.1**	7.2**	10.7	7.2**	7.2**	9.0	9.8	8.9
	-MTX	9.8	4.8**	5.3**	6.0	4.9	4.5*	5.6	5.3	6.3
HAQ-DI*	+MTX	0.79	0.57**	0.56**	0.72	0.61*	0.51**	0.55	0.60	0.59
	-MTX	0.67	0.48**	0.48**	0.46	0.46	0.54	0.45	0.45	0.58

Abbreviations: ACR20/50/70=20, 50, or 70% improvement in American College of Rheumatology criteria; Bari=baricitinib; CDAI=Clinical Disease Activity Index; HAQ-DI=Health Assessment Questionnaire-Disability Index; LTE=long-term extension; MMRM=modified model for repeated measures; MTX=methotrexate; SDAP=Simplified Disease Activity Index; Wk=week. Results are subdivided into those patients placed back on MTX (+MTX) and those who remained true Bari monotherapy (-MTX). Wks are based on time since initial randomisation in the 52-wk RA-BEGIN study. Analyses are based on a September 1, 2016 data cutoff.

*Using nonresponder imputation and baseline of RA-BEGIN. **Data are mean values.

*p<0.05, **p<0.01; p-values are based on within-group least squares mean change from LTE baseline (Wk 52) using MMRM.

Table 2. Safety through 24 Weeks in the LTE RA-BEYOND Study for Patients Not Rescued in RA-BEGIN

n (%) [EAR]		MTX to Bari		Bari to Bari		Bari+MTX to Bari	
		(N=69, +MTX); (N=67, -MTX)	(N=67, +MTX); (N=57, -MTX)	(N=87, +MTX); (N=76, -MTX)	(N=87, +MTX); (N=76, -MTX)	(N=87, +MTX); (N=76, -MTX)	(N=87, +MTX); (N=76, -MTX)
Patients with ≥1 TEAE	+MTX	28 (37.7) [87.4]	28 (41.8) [108.2]	37 (42.5) [104.0]	37 (42.5) [104.0]	37 (42.5) [104.0]	37 (42.5) [104.0]
	-MTX	19 (28.4) [88.7]	28 (49.1) [120.0]	36 (47.4) [119.2]	36 (47.4) [119.2]	36 (47.4) [119.2]	36 (47.4) [119.2]
Infections	+MTX	11 (15.9) [37.0]	14 (20.9) [54.1]	19 (21.8) [53.4]	19 (21.8) [53.4]	19 (21.8) [53.4]	19 (21.8) [53.4]
	-MTX	7 (10.4) [24.6]	10 (17.5) [42.9]	18 (23.7) [59.6]	18 (23.7) [59.6]	18 (23.7) [59.6]	18 (23.7) [59.6]
AEs that led to study drug discontinuation	+MTX	0	2 (3.0) [7.7]	0	0	0	0
	-MTX	1 (1.5) [3.5]	2 (3.5) [8.6]	2 (2.3) [6.6]	2 (2.3) [6.6]	2 (2.3) [6.6]	2 (2.3) [6.6]
Patients with ≥1 SAE	+MTX	0	6 (9.0) [23.1]	2 (2.3) [5.6]	2 (2.3) [5.6]	2 (2.3) [5.6]	2 (2.3) [5.6]
	-MTX	3 (4.5) [10.4]	2 (3.5) [8.4]	3 (3.9) [9.9]	3 (3.9) [9.9]	3 (3.9) [9.9]	3 (3.9) [9.9]
Serious infections	+MTX	0	2 (3.0) [7.7]	1 (1.1) [2.8]	1 (1.1) [2.8]	1 (1.1) [2.8]	1 (1.1) [2.8]
	-MTX	2 (3.0) [6.9]	1 (1.8) [4.2]	0	0	0	0

Abbreviations: AEs=adverse events; Bari=baricitinib; EAR=exposure adjusted incidence rate; LTE=long-term extension; MTX=methotrexate; SAE=serious adverse event; TEAE=treatment-emergent adverse event. Results are subdivided into those patients placed back on MTX (+MTX) and those who remained true Bari monotherapy (-MTX). Analyses are based on a September 1, 2016 data cutoff. Data are n (%) [EAR].

Conclusions: Switching from MTX to bari monotherapy, maintaining bari monotherapy was associated with improvements in depths of disease control during the initial 24 wks post-switch. Disease control did not significantly change after withdrawal of MTX from combination therapy. Pts who entered the LTE with suboptimal disease control after treatment with bari monotherapy may benefit from the addition of MTX. Discontinuation of MTX in pts treated with combination during the index study was associated with maintenance of response. There were no differences in important measures of safety including events that are serious or led to discontinuation.

Disclosure of Interest: R. Fleischmann Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly and Company, Merck, Pfizer, Regeneron, Roche, Sanofi Aventis, UCB, Consultant for: AbbVie, Akros, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GSK, Janssen, Eli Lilly and Company, Pfizer, Sanofi-Aventis, UCB, T. Takeuchi Consultant for: Pfizer Japan, Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, Daiichi Sankyo Co Ltd, Nipponkayaku Ltd, Janssen Pharma KK, Merck Serono Ltd, Takeda Pharma Ltd, Mitsubishi Tanabe Pharma, Astellas Pharm, Abbvie GK, Bristol-Myers KK, Asahi Kasei Medical KK, Speakers bureau: Celtrion, Nipponkayaku Ltd, Pfizer Japan, UCB Japan, Daiichi Sankyo Ltd, Takeda Pharma Ltd, Chugai Pharma Ltd, Abbvie GK, Bristol-Myers KK, Eisai Ltd, Mitsubishi Tanabe Pharma, Janssen Pharma KK, Astellas Pharma, M. Schiff Consultant for: Abbvie, Amgen, Antares, BMS, Eli Lilly and Company, J&J, Novartis, Novo Nordisk, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, D. Schlichting Employee of: Eli Lilly and Company, L. Xie Employee of: Eli Lilly and Company, M. Issa Employee of: Eli Lilly and Company, I. Stoykov Employee of: Eli Lilly and Company, J. Lisse Employee of: Eli Lilly and Company, P. Martinez-Osuna Employee of: Eli Lilly and Company, T. Rooney Employee of: Eli Lilly and Company, C. Zerbini Grant/research support from: Pfizer, Novartis, Eli Lilly and Company, Merck, Sanofi, Amgen, Celtrion, Consultant for: Merck, Pfizer, Sanofi, Eli Lilly and Company

DOI: 10.1136/annrheumdis-2017-eular.1334

SAT0059 HIGH RADIOGRAPHIC PROGRESSION IS RARE AND GETS LESS FREQUENT IN RA PATIENTS OF THE SWISS SCQM COHORT FROM 1998 TO 2015

R. Mueller¹, R. Thalmann¹, H. Schulze-Koops², N. Graf³, J. von Kempis¹.

¹Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland;

²Rheumaeinheit, Klinikum der Universität München, Campus Innenstadt, Munich, Germany;

³Graf Biostatistics, Winterthur, Switzerland

Background: The primary goal of current therapeutic strategies in RA is to control disease activity and at the same time to prevent radiographic progression. A disconnect between a missing radiographic progression and higher disease activity under treatment with biologic agents has been discussed. In general, analyses of radiographic progression in RA rather focus on radiographic non-progression or repair and high radiographic progression in spite of therapy has, to our knowledge not been analysed in detail in the last years, neither in RCTs nor in cohort studies.

Objectives: To analyse the occurrence of high radiographic destruction and its development in the era of biologic treatment.

Methods: We included all RA patients from the Swiss registry SCQM with at least two subsequently scored radiographs. Radiographic destruction was scored with the Ratingen erosion score and calculated by dividing the change of Ratingen scores by time (>6 months) between two subsequent radiographs. To analyse high radiographic progression we looked for the height and time of the highest (peak) radiographic progression in every individual patient for the analysis. The individual peak radiographic progression was analysed in groups as change of Ratingen scores/year: 0-≤10, 10-≤20, 20-≤30, >30 (groups 1-4). The time point of the individual peak radiographic progression was analysed per group (follow up 1998 – 2015). The baseline disease characteristics were compared using standard descriptive statistics (Kruskal-Wallis or Chi-square tests).

Results: 4'033 patients were included into the analysis. 3'049 patients had a peak radiographic progression between 0 and ≤10/year, 773 between 10 and ≤20, 150 between 20 and ≤30, and 61 of >30. All patient groups were within the same age range (mean: 56.5 – 60.5 years). Rheumatoid factor and ACPA were more frequent in patient groups with higher peak radiographic progression (RF: 73.6, 80.0, 88.9, 90.0; ACPA: 66.8, 73.4, 74.3, 82.1, groups 1-4, respectively). When the rate of radiographic progression before and after peak progression was analysed, 69.7%, 74.7%, 76.9%, and 93.3% of the patients had a radiographic progression of 25% or lower as compared to peak progression before and 76.1%, 81.8%, 91.1%, and 93.8% after this peak progression, respectively for patients in groups 1 to 4 (Figure A).

The disease activity, as assessed by DAS 28, was significantly higher in all patient groups before peak progression and lower thereafter (Figure B, p<0.001). Average HAQ-DI scores increased after peak radiographic progression in group 4 (Figure C, p=0.005) whereas it is stable or even decreases among the patients of the other patient groups.

Conclusions: High peak radiographic progression is a rare phenomenon that gets less frequent in patients over the last years of observation. This may be an effect of modern therapy. Among the patients with high radiographic progression, (1) a greater delay between diagnosis and first symptoms was found and (2) the use of biologic agents was less frequent. These data suggest that the decreasing frequency of very high radiographic peak progression in the Swiss RA patients reflect a more effective therapeutic approach in the last years.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4232

SAT0060 RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS DIFFERS DEPENDING ON RHEUMATOID FACTOR LEVELS IN ANTI-CITRULLINATED POSITIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

S. Bugatti, A. Manzo, G. Zanframundo, F. Benaglio, G. Sakellariou, C. Montecucco, R. Caporali. *Rheumatology and Translational Immunology Research Laboratories (LaRIT) and Early Arthritis Clinic, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy*

Background: In rheumatoid arthritis (RA), several autoantibody characteristics, including specificities, levels and isotypes, may influence their pathogenic properties and impact on clinical presentation and outcomes of the disease (1, 2). In particular, classical IgM rheumatoid factor (RF) may boost inflammation triggered by anti-citrullinated protein antibodies (ACPA) (3).

Objectives: To investigate whether RF impacts on disease characteristics and response to therapy in ACPA-positive early RA patients treated with conventional synthetic disease modifying drugs (csDMARDs).

Methods: 574 early RA patients consecutively enrolled in our Early Arthritis Clinic between 2005 and 2014 were included. Patients had symptoms' duration <12 months, were glucocorticoid- and DMARD-naïve, and fulfilled RA criteria at inclusion. IgM RF and IgG ACPA were determined in baseline sera by immunonephelometry and a second-generation ELISA CCP assay respectively. Autoantibody levels were considered high when >3 times the upper limit of normal (ULN). Patients were treated with incremental doses of methotrexate according to a treat-to-target strategy aiming at low disease activity (LDA, DAS28 ≤3.2). The associations between autoantibody specificities and levels and the achievement of LDA and disease remission (DAS28 <2.6) over 6 months were investigated by Cox regression.

Results: 360 patients tested RF and/or ACPA positive (31.9% single RF-positive, 10.3% single ACPA-positive, 57.8% ACPA and RF double-positive) and were

selected for outcome analyses. Among seropositive patients, both LDA and remission were less frequently achieved in case of RF-positivity. Relevantly, in ACPA-positive patients ($n=273$), the co-occurrence of RF dose-dependently influenced clinical outcomes. After 6 months of treatment, LDA and disease remission were achieved respectively by 69.6% and 47.8% of single ACPA-positive, 68.8% and 37.5% of ACPA-positive RF-low, and 57% and 27.6% of ACPA-positive RF-high patients (chi-square for trend $p=0.18$ for LDA, $p=0.05$ for remission). After adjusting for confounders (age, gender, symptoms' duration, baseline disease activity, use of prednisone, recruitment period), high levels of RF independently predicted failure to achieve LDA with an HR (95% CI) of 0.61 (0.39 to 0.95) and failure to achieve remission with an HR (95% CI) of 0.63 (0.35 to 0.99) (Figure 1). In contrast, ACPA levels did not show any significant predictive value, neither for thresholds of >3 ULN nor of >100 U.

Conclusions: Among ACPA-positive RA patients, disease characteristics may vary in association with the extent of overall humoral autoimmunity. In particular, the concomitant presence of high levels of IgM RF seems associated with lower response rates to csDMARDs. Collectively, these findings highlight the importance of further subclassifying patients with autoantibody-positive RA in order get deeper insights into disease mechanisms and clinical outcomes.

References:

- [1] Aletaha D et al. *Arthritis Res Ther* 2015;17:229.
- [2] Derksen VFAM et al. *Ann Rheum Dis* 2017;doi:10.1136/annrheumdis-2016-209794.
- [3] Sokolove J et al. *Arthritis Rheumatol* 2014;66:813–21.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5778

SAT0061 HAQ SCORE IS AN INDEPENDENT PREDICTOR OF SUSTAINED REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS

S.-S. Lee^{1,1}, J.-H. Kang, J.-E. Kim, K.-E. Lee, D.-J. Park. *Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic Of*

Objectives: We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the 2-year follow-up.

Methods: We obtained data on 291 RA outpatients, seen from July 2009 to September 2012. Sociodemographic data and answers to questionnaires were collected in face-to-face interviews. Remission was defined according to the Disease Activity Score in 28 joints (DAS28)-ESR, DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and ACR/EULAR Boolean definition. Sustained remission was defined as when the patient continued in remission at two consecutive annual assessments. Predictors of sustained remission according to the DAS28-CRP were assessed by univariate and multivariate analyses.

Results: For the 291 RA patients, the remission rates of RA were 17.9% (DAS28-ESR), 54.3% (DAS28-CRP), 10.3% (SDAI), 10.0% (CDAI), and 5.8% (Boolean). On follow-up for 2 years, the sustained remission rates of RA were 46.5% (DAS28), 55.0% (DAS28-CRP), 37.5% (SDAI), 32.0% (CDAI), and 30.8% (Boolean). RA patients who achieve sustained remission according to the DAS28-CRP were younger, and had more education, higher monthly income, lower Health Assessment Questionnaire (HAQ) score, lower physician global assessment, lower patient global assessment, lower patient pain assessment, and higher EQ-5D. In multivariate analysis, only the HAQ score predicted sustained remission according to DAS28-CRP (OR=0.257, 95% CI 0.067–0.980, $p=0.047$).

Conclusions: The remission rates of RA patients differed according to the definition of remission, and the highest sustained remission rate was classified by the DAS28-CRP. A lower HAQ score was an independent predictor of sustained remission over 2 years, according to the DAS28-CRP.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2363

SAT0062 14-3-3ETA PREDICTS JOINT DAMAGE PROGRESSION AND FLARING AFTER ADALIMUMAB DISCONTINUATION

S. Hirata^{1,2}, A. Marotta³, K. Hanami², Y. Tanaka². ¹Hiroshima University Hospital, Hiroshima; ²University of Occupational and Environmental Health, Kitakyushu, Japan; ³Augurex Life Sciences Corp, Vancouver, Canada

Background: The HONOR (humira discontinuation without functional and radio-

graphic damage following sustained remission) study was designed to investigate the possibility of patients discontinuing adalimumab (ADA) therapy for 1 year without flaring (DAS28-ESR ≥ 3.2). 14-3-3 η is a mechanistic serum marker that is modifiable over the disease course, does not correlate with CRP and is a predictor of radiographic progression even in patients who achieve clinical remission. The uncoupling of inflammation and joint damage processes in RA underscores a risk of premature discontinuation of biologic treatment when aiming to achieve sustained remission. Serum markers that could indicate which patients are at risk of flare and continued joint damage despite clinical remission are highly desirable.

Objectives: In this study, serum 14-3-3 η was investigated as a predictor of joint damage and flares in the HONOR cohort.

Methods: Serum 14-3-3 η levels were measured in 62 Japanese patients, 51 of which were from the HONOR study at baseline, 1-year after treatment initiation, at discontinuation and at the time of flare. Of the 62 patients, 46 (74%) patients achieved sustained drug-free remission up to 1 year following ADA discontinuation. Sharp van der Heijde (SHS) scores were available at therapy initiation, discontinuation, and at 52 weeks following. Relationships between continuous variables were assessed using uni- and multi-variable Gaussian linear regression models and logistic regression.

Results: At baseline and discontinuation, median (QR) 14-3-3 η levels were 0.28 ng/ml (0.07–2.11) and 0.22 ng/ml (0.04–1.28) respectively, with 26 (59%) of 44 and 29 (54%) of 54 patients being positive (≥ 0.19 ng/ml) at the corresponding time-points. Paired t-test revealed that levels of 14-3-3 η were significantly different between baseline and discontinuation, $p=0.030$. Level of 14-3-3 η at baseline was positively associated with SHS at 12 months and at the time of flare, $p=0.038$. Bivariable modeling revealed that baseline 14-3-3 η together with the change in 14-3-3 η had a significant interacting effect on SHS at 12 months and the time of flare, $p=0.02$. Higher baseline 14-3-3 η levels together with an increase in levels at the time of discontinuation was strongly associated with an increased SHS. Adding CRP, flare, sustained remission through 12 months, MTX dose at initiation and at ADA discontinuation did not improve predictive effects of 14-3-3 η with SHS. Baseline 14-3-3 η levels alone was not associated with flares at 12 months ($p=0.15$) however when combined with CRP, a significant interaction was present ($p=0.03$). Specifically, patients with a low CRP, and a high 14-3-3 η level had a higher likelihood of flaring versus those with a low 14-3-3 η , 22% versus 12%.

Conclusions: Baseline 14-3-3 η and increases in its levels are associated with worse radiographic outcomes in patients who achieve clinical remission and discontinue ADA. To reduce the risk of flare in patients who are candidates for discontinuation of ADA, CRP and 14-3-3 η measurements should be considered in combination as markers of flare prediction.

Disclosure of Interest: S. Hirata: None declared, A. Marotta Employee of: Augurex Life Sciences Corp., K. Hanami: None declared, Y. Tanaka: None declared
DOI: 10.1136/annrheumdis-2017-eular.5426

SAT0063 A PROSPECTIVE STUDY ON COMPARISON OF COMPOSITE INDICES WITH ULTRASOUND FOR DETECTING REMISSION AND PREDICTION OF FLARE IN 2 YEARS

M.O. Olmez¹, E.K. Gunal², S.B. Ureyen³, H. Keskin², A.B. Ozturk⁴, H.G. Yeter⁵, E. Cobanoglu⁵, S.Z. Aydin³. ¹Internal Medicine; ²Rheumatology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey; ³Rheumatology, University of Ottawa, Faculty of Medicine, Ottawa, Canada; ⁴Allergy and Immunology; ⁵Koc University, School of Medicine, Istanbul, Turkey

Background: Treat-to-target (T2T) approach suggests using a composite index when following patients with rheumatoid arthritis (RA) without identifying which one to use.

Objectives: In this prospective study we aimed to compare the accuracy of different indices for RA patients in remission taking Ultrasound Global Synovitis Score (GLOESS) as a gold standard and their predictive value for flares in 2 years.

Methods: RA patients who were considered to be in clinical remission according to the clinician were recruited. Disease activity was assessed using DAS28-CRP, CDAI, SDAI and RAPID-3 and 38 joints per patient were scanned by US and scored according to GLOESS. The total GLOESS scores were calculated for 38 joints and also for 28 joints by excluding the MTP joints. The number of joints with ≥ 2 GLOESS was calculated. Flare data was collected in 3 subsequent visits in the following 2 years, whenever available.

Results: Ninety-six consecutive patients (80.2% females) were recruited. Patients were more frequently categorized as being in remission using DAS28 (80%) compared to CDAI (50%), SDAI (45.2%) and RAPID 3 (37.5%). Patients that were in remission according to CDAI had lower GLOESS scores on 28 joints ($p=0.05$) and had less joints with ≥ 2 signals ($p=0.04$) (table). For SDAI patients in remission had significantly less number of joints with grade 3 signals ($p=0.03$) and tend to have lower GLOESS scores on 28 joints as well as lower number of joints with ≥ 2 signals ($p=0.06$). None of the US scores were able to differentiate different disease states according to DAS28-CRP or RAPID. Flare data was available in 76 patients, 22 of whom had flares. Patients that had flare had higher GLOESS scores on 28 joints at baseline ($p=0.05$) and tend to have higher number of joints with grade 3 signals ($p=0.06$). Although numerically higher, none of the clinical indices were able to predict flares based on remission status (remission vs non remission: CDAI: 22.5% vs 36.1, $p=0.2$; SDAI: 22.9 vs 36.8, $p=0.2$; DAS28: 25.4% vs 50%, $p=0.1$; RAPID3: 20% vs 34.8%, $p=0.2$).